Platelet activation in obesity and metabolic syndrome

Obesity Reviews

Volumn 13, Issue 1, 2012, Pages 27-42

  Santilli, F ^a   Vazzana, N ^a   Liani, R ^a   Guagnano, M T ^a   Davi G ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Atherothrombosis; Metabolic syndrome; Obesity; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; AMYLOID PRECURSOR PROTEIN; ANTIOBESITY AGENT; ARACHIDONATE 5 LIPOXYGENASE; CD36 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR2; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LEPTIN; MYELOPEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PADGEM PROTEIN; SCAVENGER RECEPTOR BI; STROMAL CELL DERIVED FACTOR 1; THROMBOXANE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ARTERY THROMBOSIS; BARIATRIC SURGERY; CARDIOVASCULAR RISK; CELL INTERACTION; CORONARY ARTERY DISEASE; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTE VOLUME; WEIGHT REDUCTION;

ASPIRIN; BLOOD PLATELETS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; METABOLIC SYNDROME X; OBESITY; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; THROMBOSIS;

EID: 83855165740     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2011.00930.x     Document Type: Review

References (157)

1. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-241.
2. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2010; 375: 181-183.
3. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM etal. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 2011; 123: e18-e209.
4. Arnlov J, Ingelsson E, Sundstrom J, Lind L. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 2010; 121: 230-236.
5. Lind L, Siegbahn A, Ingelsson E, Sundstrom J, Arnlov J. A detailed cardiovascular characterization of obesity without the metabolic syndrome. Arterioscler Thromb Vasc Biol 2011; 31: e27-e34.
6. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444: 875-880.
7. Waki H, Tontonoz P. Endocrine functions of adipose tissue. Annu Rev Pathol 2007; 2: 31-56.
8. Beijers HJ, Ferreira I, Spronk HM, Bravenboer B, Dekker JM, Nijpels G etal. Body composition as determinant of thrombin generation in plasma: the Hoorn study. Arterioscler Thromb Vasc Biol 2010; 30: 2639-2647.
9. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev 2002; 3: 85-101.
10. Anfossi G, Russo I, Trovati M. Platelet dysfunction in central obesity. Nutr Metab Cardiovasc Dis 2009; 19: 440-449.
11. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996; 7: 157-161.
12. Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract 2009; 63: 1509-1515.
13. Coban E, Ozdogan M, Yazicioglu G, Akcit F. The mean platelet volume in patients with obesity. Int J Clin Pract 2005; 59: 981-982.
14. Coban E, Yilmaz A, Sari R. The effect of weight loss on the mean platelet volume in obese patients. Platelets 2007; 18: 212-216.
15. Tavil Y, Sen N, Yazici HU, Hizal F, Abaci A, Cengel A. Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. Thromb Res 2007; 120: 245-250.
16. Arslan N, Makay B. Mean platelet volume in obese adolescents with nonalcoholic fatty liver disease. J Pediatr Endocrinol Metab 2010; 23: 807-813.
17. Ozhan H, Aydin M, Yazici M, Yazgan O, Basar C, Gungor A etal. Mean platelet volume in patients with non-alcoholic fatty liver disease. Platelets 2010; 21: 29-32.
18. Kimura H, Ishibashi T, Shikama Y, Okano A, Akiyama Y, Uchida T etal. Interleukin-1 beta (IL-1 beta) induces thrombocytosis in mice: possible implication of IL-6. Blood 1990; 76: 2493-2500.
19. Battinelli E, Willoughby SR, Foxall T, Valeri CR, Loscalzo J. Induction of platelet formation from megakaryocytoid cells by nitric oxide. Proc Natl Acad Sci U S A 2001; 98: 14458-14463.
20. Guthikonda S, Lev EI, Patel R, DeLao T, Bergeron AL, Dong JF etal. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007; 5: 490-496.
21. Vaduganathan M, Alviar CL, Arikan ME, Tellez A, Guthikonda S, DeLao T etal. Platelet reactivity and response to aspirin in subjects with the metabolic syndrome. Am Heart J 2008; 156: 1002 e1-1002 e7.
22. Sato C, Shikata K, Hirota D, Sasaki M, Nishishita S, Miyamoto S etal. P-selectin glycoprotein ligand-1 deficiency is protective against obesity-related insulin resistance. Diabetes 2011; 60: 189-199.
23. De Pergola G, Pannacciulli N, Coviello M, Scarangella A, Di Roma P, Caringella M etal. sP-selectin plasma levels in obesity: association with insulin resistance and related metabolic and prothrombotic factors. Nutr Metab Cardiovasc Dis 2008; 18: 227-232.
24. Angelico F, Alessandri C, Ferro D, Pignatelli P, Del Ben M, Fiorello S etal. Enhanced soluble CD40L in patients with the metabolic syndrome: relationship with in vivo thrombin generation. Diabetologia 2006; 49: 1169-1174.
25. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98: 1047-1054.
26. Santilli F, Basili S, Ferroni P, Davì G. CD40/CD40L system and vascular disease. Intern Emerg Med 2007; 2: 256-268.
27. Poggi M, Jager J, Paulmyer-Lacroix O, Peiretti F, Gremeaux T, Verdier M etal. The inflammatory receptor CD40 is expressed on human adipocytes: contribution to crosstalk between lymphocytes and adipocytes. Diabetologia 2009; 52: 1152-1163.
28. Missiou A, Wolf D, Platzer I, Ernst S, Walter C, Rudolf P etal. CD40L induces inflammation and adipogenesis in adipose cells - a potential link between metabolic and cardiovascular disease. Thromb Haemost 2010; 103: 788-796.
29. Barry OP, Pratico D, Savani RC, FitzGerald GA. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest 1998; 102: 136-144.
30. Serebruany VL, Malinin A, Ong S, Atar D. Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease. J Thromb Thrombolysis 2008; 25: 207-213.
31. Murakami T, Horigome H, Tanaka K, Nakata Y, Ohkawara K, Katayama Y etal. Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity. Thromb Res 2007; 119: 45-53.
32. Davì G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M etal. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002; 288: 2008-2014.
33. Basili S, Pacini G, Guagnano MT, Manigrasso MR, Santilli F, Pettinella C etal. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol 2006; 48: 2531-2538.
34. Patrono C, Falco A, Davì G. Isoprostane formation and inhibition in atherothrombosis. Curr Opin Pharmacol 2005; 5: 198-203.
35. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2003; 23: 2131-2137.
36. Ferro D, Basili S, Roccaforte S, Di Franco M, Cipollone F, Ciabattoni G etal. Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2689-2697.
37. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494.
38. May AE, Seizer P, Gawaz M. Platelets: inflammatory firebugs of vascular walls. Arterioscler Thromb Vasc Biol 2008; 28: s5-s10.
39. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100: 27-40.
40. Ueba T, Nomura S, Inami N, Nishikawa T, Kajiwara M, Iwata R etal. Correlation and association of plasma interleukin-6 and plasma platelet-derived microparticles, markers of activated platelets, in healthy individuals. Thromb Res 2010; 125: e329-e334.
41. Jylhava J, Haarala A, Eklund C, Pertovaara M, Kahonen M, Hutri-Kahonen N etal. Serum amyloid A is independently associated with metabolic risk factors but not with early atherosclerosis: the Cardiovascular Risk in Young Finns Study. J Intern Med 2009; 266: 286-295.
42. Urieli-Shoval S, Shubinsky G, Linke RP, Fridkin M, Tabi I, Matzner Y. Adhesion of human platelets to serum amyloid A. Blood 2002; 99: 1224-1229.
43. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008; 29: 2959-2971.
44. Pignatelli P, De Biase L, Lenti L, Tocci G, Brunelli A, Cangemi R etal. Tumor necrosis factor-alpha as trigger of platelet activation in patients with heart failure. Blood 2005; 106: 1992-1994.
45. Eisenhardt SU, Habersberger J, Murphy A, Chen YC, Woollard KJ, Bassler N etal. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res 2009; 105: 128-137.
46. Aukrust P, Halvorsen B, Ueland T, Michelsen AE, Skjelland M, Gullestad L etal. Activated platelets and atherosclerosis. Expert Rev Cardiovasc Ther 2010; 8: 1297-1307.
47. Troseid M, Lappegard KT, Claudi T, Damas JK, Morkrid L, Brendberg R etal. Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndrome. Eur Heart J 2004; 25: 349-355.
48. Unek IT, Bayraktar F, Solmaz D, Ellidokuz H, Yuksel F, Sisman AR etal. Enhanced levels of soluble CD40 ligand and C-reactive protein in a total of 312 patients with metabolic syndrome. Metabolism 2010; 59: 305-313.
49. Ferroni P, Martini F, Cardarello CM, Gazzaniga PP, Davì G, Basili S. Enhanced interleukin-1beta in hypercholesterolemia: effects of simvastatin and low-dose aspirin. Circulation 2003; 108: 1673-1675.
50. Fateh-Moghadam S, Li Z, Ersel S, Reuter T, Htun P, Plockinger U etal. Platelet degranulation is associated with progression of intima-media thickness of the common carotid artery in patients with diabetes mellitus type 2. Arterioscler Thromb Vasc Biol 2005; 25: 1299-1303.
51. Zimmerman GA, Weyrich AS. Signal-dependent protein synthesis by activated platelets: new pathways to altered phenotype and function. Arterioscler Thromb Vasc Biol 2008; 28: s17-s24.
52. Freedman JE, Larson MG, Tanriverdi K, O'Donnell CJ, Morin K, Hakanson AS etal. Relation of platelet and leukocyte inflammatory transcripts to body mass index in the Framingham heart study. Circulation 2010; 122: 119-129.
53. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801.
54. Falcon C, Pfliegler G, Deckmyn H, Vermylen J. The platelet insulin receptor: detection, partial characterization, and search for a function. Biochem Biophys Res Commun 1988; 157: 1190-1196.
55. Trovati M, Anfossi G, Cavalot F, Massucco P, Mularoni E, Emanuelli G. Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo. Diabetes 1988; 37: 780-786.
56. Trovati M, Anfossi G, Massucco P, Mattiello L, Costamagna C, Piretto V etal. Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-3′, 5′-cyclic monophosphate and adenosine-3′, 5′-cyclic monophosphate. Diabetes 1997; 46: 742-749.
57. Hajek AS, Joist JH, Baker RK, Jarett L, Daughaday WH. Demonstration and partial characterization of insulin receptors in human platelets. J Clin Invest 1979; 63: 1060-1065.
58. Touyz RM, Schiffrin EL. Blunted inhibition by insulin of agonist-stimulated calcium, pH and aggregatory responses in platelets from hypertensive patients. J Hypertens 1994; 12: 1255-1263.
59. Anfossi G, Russo I, Trovati M. Platelet resistance to the anti-aggregating agents in the insulin resistant states. Curr Diabetes Rev 2006; 2: 409-430.
60. Trovati M, Mularoni EM, Burzacca S, Ponziani MC, Massucco P, Mattiello L etal. Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients. Diabetes 1995; 44: 1318-1322.
61. Anfossi G, Russo I, Massucco P, Mattiello L, Doronzo G, De Salve A etal. Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity. Eur J Clin Invest 2004; 34: 482-489.
62. Anfossi G, Russo I, Doronzo G, Pomero A, Trovati M. Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells. Mediators Inflamm 2010; 2010: 174341.
63. Russo I, Traversa M, Bonomo K, De Salve A, Mattiello L, Del Mese P etal. In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin. Obesity 2010; 18: 788-797.
64. Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001; 108: 1533-1540.
65. Guagnano MT, Romano M, Falco A, Nutini M, Marinopiccoli M, Manigrasso MR etal. Leptin increase is associated with markers of the hemostatic system in obese healthy women. J Thromb Haemost 2003; 1: 2330-2334.
66. Nakata M, Yada T, Soejima N, Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999; 48: 426-429.
67. Kato H, Kashiwagi H, Shiraga M, Tadokoro S, Kamae T, Ujiie H etal. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 2006; 26: 224-230.
68. Elbatarny HS, Netherton SJ, Ovens JD, Ferguson AV, Maurice DH. Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: implication in obesity-associated cardiovascular diseases. Eur J Pharmacol 2007; 558: 7-13.
69. Restituto P, Colina I, Varo JJ, Varo N. Adiponectin diminishes platelet aggregation and sCD40L release. Potential role in the metabolic syndrome. Am J Physiol Endocrinol Metab 2010; 298: E1072-E1077.
70. Manigrasso MR, Ferroni P, Santilli F, Taraborelli T, Guagnano MT, Michetti N etal. Association between circulating adiponectin and interleukin-10 levels in android obesity: effects of weight loss. J Clin Endocrinol Metab 2005; 90: 5876-5879.
71. Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K etal. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004; 109: 2046-2049.
72. Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci 2009; 84: 705-712.
73. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y etal. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-1761.
74. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002; 23: 599-622.
75. Sonnenberg GE, Krakower GR, Kissebah AH. A novel pathway to the manifestations of metabolic syndrome. Obes Res 2004; 12: 180-186.
76. Otani H. Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome. Antioxid Redox Signal 2011; 15: 1911-1926.
77. Forstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med 2008; 5: 338-349.
78. Freedman JE. Oxidative stress and platelets. Arterioscler Thromb Vasc Biol 2008; 28: s11-s16.
79. Victor VM, Rocha M, Sola E, Banuls C, Garcia-Malpartida K, Hernandez-Mijares A. Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharm Des 2009; 15: 2988-3002.
80. Audoly LP, Rocca B, Fabre JE, Koller BH, Thomas D, Loeb AL etal. Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation 2000; 101: 2833-2840.
81. Davì G, Alessandrini P, Mezzetti A, Minotti G, Bucciarelli T, Costantini F etal. In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17: 3230-3235.
82. Guagnano MT, Ferroni P, Santilli F, Paoletti V, Manigrasso MR, Pescara L etal. Determinants of platelet activation in hypertensives with microalbuminuria. Free Radic Biol Med 2009; 46: 922-927.
83. Davì G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S etal. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224-229.
84. Ferrante E, Vazzana N, Santilli F, Di Cicco M, Lauriti C, Di Battista L etal. Determinants of thromboxane biosynthesis in rheumatoid arthritis: role of RAGE and oxidant stress. Free Radic Biol Med 2010; 49: 857-864.
85. Helal O, Defoort C, Robert S, Marin C, Lesavre N, Lopez-Miranda J etal. Increased levels of microparticles originating from endothelial cells, platelets and erythrocytes in subjects with metabolic syndrome: relationship with oxidative stress. Nutr Metab Cardiovasc Dis 2010 Apr 14. [Epub ahead of print].
86. Pignatelli P, Sanguigni V, Lenti L, Ferro D, Finocchi A, Rossi P etal. gp91phox-dependent expression of platelet CD40 ligand. Circulation 2004; 110: 1326-1329.
87. Pignatelli P, Carnevale R, Di Santo S, Bartimoccia S, Sanguigni V, Lenti L etal. Inherited human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction. Arterioscler Thromb Vasc Biol 2011; 31: 423-434.
88. Begonja AJ, Gambaryan S, Geiger J, Aktas B, Pozgajova M, Nieswandt B etal. Platelet NAD(P)H-oxidase-generated ROS production regulates alphaIIbbeta3-integrin activation independent of the NO/cGMP pathway. Blood 2005; 106: 2757-2760.
89. Krotz F, Sohn HY, Keller M, Gloe T, Bolz SS, Becker BF etal. Depolarization of endothelial cells enhances platelet aggregation through oxidative inactivation of endothelial NTPDase. Arterioscler Thromb Vasc Biol 2002; 22: 2003-2009.
90. De Cristofaro R, Rocca B, Vitacolonna E, Falco A, Marchesani P, Ciabattoni G etal. Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. J Thromb Haemost 2003; 1: 250-256.
91. Santilli F, Vazzana N, Bucciarelli LG, Davì G. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem 2009; 16: 940-952.
92. Vazzana N, Santilli F, Cuccurullo C, Davì G. Soluble forms of RAGE in internal medicine. Intern Emerg Med 2009; 4: 389-401.
93. Varo N, Libby P, Nuzzo R, Italiano J, Doria A, Schonbeck U. Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products. Diab Vasc Dis Res 2005; 2: 81-87.
94. Lancellotti S, De Filippis V, Pozzi N, Peyvandi F, Palla R, Rocca B etal. Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: a new prothrombotic mechanism in diseases associated with oxidative stress. Free Radic Biol Med 2010; 48: 446-456.
95. Davì G, Romano M, Mezzetti A, Procopio A, Iacobelli S, Antidormi T etal. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation 1998; 97: 953-957.
96. Pignatelli P, Sanguigni V, Paola SG, Lo Coco E, Lenti L, Violi F. Vitamin C inhibits platelet expression of CD40 ligand. Free Radic Biol Med 2005; 38: 1662-1666.
97. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 2002; 105: 2107-2111.
98. Thomas GN, Chook P, Qiao M, Huang XS, Leong HC, Celermajer DS etal. Deleterious impact of 'high normal' glucose levels and other metabolic syndrome components on arterial endothelial function and intima-media thickness in apparently healthy Chinese subjects: the CATHAY study. Arterioscler Thromb Vasc Biol 2004; 24: 739-743.
99. Bendall JK, Rinze R, Adlam D, Tatham AL, de Bono J, Wilson N etal. Endothelial Nox2 overexpression potentiates vascular oxidative stress and hemodynamic response to angiotensin II: studies in endothelial-targeted Nox2 transgenic mice. Circ Res 2007; 100: 1016-1025.
100. Hamburg NM, Larson MG, Vita JA, Vasan RS, Keyes MJ, Widlansky ME etal. Metabolic syndrome, insulin resistance, and brachial artery vasodilator function in Framingham Offspring participants without clinical evidence of cardiovascular disease. Am J Cardiol 2008; 101: 82-88.
101. Romero-Corral A, Sert-Kuniyoshi FH, Sierra-Johnson J, Orban M, Gami A, Davison D etal. Modest visceral fat gain causes endothelial dysfunction in healthy humans. J Am Coll Cardiol 2010; 56: 662-666.
102. Nachman RL, Rafii S. Platelets, petechiae, and preservation of the vascular wall. N Engl J Med 2008; 359: 1261-1270.
103. Dernbach E, Randriamboavonjy V, Fleming I, Zeiher AM, Dimmeler S, Urbich C. Impaired interaction of platelets with endothelial progenitor cells in patients with cardiovascular risk factors. Basic Res Cardiol 2008; 103: 572-581.
104. Santilli F, Romano M, Recchiuti A, Dragani A, Falco A, Lessiani G etal. Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. Blood 2008; 112: 1085-1090.
105. Violi F, Sanguigni V, Carnevale R, Plebani A, Rossi P, Finocchi A etal. Hereditary deficiency of gp91(phox) is associated with enhanced arterial dilatation: results of a multicenter study. Circulation 2009; 120: 1616-1622.
106. Pignatelli P, Carnevale R, Cangemi R, Loffredo L, Sanguigni V, Stefanutti C etal. Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol 2010; 30: 360-367.
107. Angelico F, Loffredo L, Pignatelli P, Augelletti T, Carnevale R, Pacella A etal. Weight loss is associated with improved endothelial dysfunction via NOX2-generated oxidative stress down-regulation in patients with the metabolic syndrome. Intern Emerg Med 2011 Apr 22. [Epub ahead of print].
108. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA etal. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
109. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA etal. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
110. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23: 1499-1504.
111. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG etal. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345: 790-797.
112. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R etal. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289: 1799-1804.
113. You T, Berman DM, Ryan AS, Nicklas BJ. Effects of hypocaloric diet and exercise training on inflammation and adipocyte lipolysis in obese postmenopausal women. J Clin Endocrinol Metab 2004; 89: 1739-1746.
114. Gelfand EV, Cannon CP. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol 2006; 47: 1919-1926.
115. Wang Q, Perrard XD, Perrard JL, Mansoori A, Smith CW, Ballantyne CM etal. Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity. Obesity 2010; 19: 505-513.
116. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D etal. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235-242.
117. Bougoulia M, Triantos A, Koliakos G. Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women. Hormones (Athens) 2006; 5: 259-269.
118. Samuelsson L, Gottsater A, Lindgarde F. Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors. Diabetes Obes Metab 2003; 5: 195-201.
119. Desilets AR, Dhakal-Karki S, Dunican KC. Role of metformin for weight management in patients without type 2 diabetes. Ann Pharmacother 2008; 42: 817-826.
120. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
121. Meaney E, Vela A, Samaniego V, Meaney A, Asbun J, Zempoalteca J-C etal. Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study. Clin Exp Pharmacol Physiol 2008; 35: 895-903.
122. Gargiulo P, Caccese D, Pignatelli P, Brufani C, De Vito F, Marino R etal. Metformin decreases platelet superoxide anion production in diabetic patients. Diabetes Metab Res Rev 2002; 18: 156-159.
123. Leverve XM, Guigas B, Detaille D, Batandier C, Koceir EA, Chauvin C etal. Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 2003; 29: 6S88-6S94.
124. Formoso G, De Filippis EA, Michetti N, Di Fulvio P, Pandolfi A, Bucciarelli T etal. Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. Diabetes Metab Res Rev 2008; 24: 231-237.
125. Santilli F, Formoso G, Sbraccia P, Averna M, Miccoli R, Di Fulvio P etal. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. J Thromb Haemost 2010; 8: 828-837.
126. DeMaria EJ. Bariatric surgery for morbid obesity. N Engl J Med 2007; 356: 2176-2183.
127. Sjostrom L, Lindroos A-K, Peltonen M, Torgerson J, Bouchard C, Carlsson B etal. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-2693.
128. Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD etal. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357: 753-761.
129. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H etal. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-752.
130. Kopp HP, Kopp CW, Festa A, Krzyzanowska K, Kriwanek S, Minar E etal. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 2003; 23: 1042-1047.
131. Schernthaner GH, Kopp HP, Kriwanek S, Krzyzanowska K, Satler M, Koppensteiner R etal. Effect of massive weight loss induced by bariatric surgery on serum levels of interleukin-18 and monocyte-chemoattractant-protein-1 in morbid obesity. Obes Surg 2006; 16: 709-715.
132. Habib P, Scrocco JD, Terek M, Vanek V, Mikolich JR. Effects of bariatric surgery on inflammatory, functional and structural markers of coronary atherosclerosis. Am J Cardiol 2009; 104: 1251-1255.
133. Schernthaner GH, Kopp HP, Krzyzanowska K, Kriwanek S, Koppensteiner R, Schernthaner G. Soluble CD40L in patients with morbid obesity: significant reduction after bariatric surgery. Eur J Clin Invest 2006; 36: 395-401.
134. Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG, Montalescot G etal. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 2008; 118: 1705-1712.
135. Tamminen M, Lassila R, Westerbacka J, Vehkavaara S, Yki-Jarvinen H. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord 2003; 27: 907-911.
136. Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A etal. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin 'resistance'. J Am Coll Cardiol 2009; 53: 667-677.
137. Rocca B, Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 2005; 3: 1597-1602.
138. Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006; 37: 2153-2158.
139. Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D etal. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005; 46: 1258-1263.
140. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987; 69: 180-186.
141. Bordeaux BC, Qayyum R, Yanek LR, Vaidya D, Becker LC, Faraday N etal. Effect of obesity on platelet reactivity and response to low-dose aspirin. Prev Cardiol 2010; 13: 56-62.
142. Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L etal. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A 2002; 99: 7634-7639.
143. Dragani A, Pascale S, Recchiuti A, Mattoscio D, Lattanzio S, Petrucci G etal. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood 2010; 115: 1054-1061.
144. Denis MM, Tolley ND, Bunting M, Schwertz H, Jiang H, Lindemann S etal. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell 2005; 122: 379-391.
145. Evangelista V, Manarini S, Di Santo A, Capone ML, Ricciotti E, Di Francesco L etal. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res 2006; 98: 593-595.
146. Davì G, Santilli F. Aspirin as antiplatelet agent in diabetes. PROS. Eur J Intern Med 2010; 21: 149-153.
147. Modica A, Karlsson F, Mooe T. Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection. J Thromb Haemost 2007; 5: 507-511.
148. Santilli F, Mucci L, Davì G. TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus. Intern Emerg Med 2011; 6: 203-212.
149. Chakraborty K, Khan GA, Banerjee P, Ray U, Sinha AK. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin. Platelets 2003; 14: 421-427.
150. Williams PC, Coffey MJ, Coles B, Sanchez S, Morrow JD, Cockcroft JR etal. In vivo aspirin supplementation inhibits nitric oxide consumption by human platelets. Blood 2005; 106: 2737-2743.
151. Boutaud O, Oates JA. Study of inhibitors of the PGH synthases for which potency is regulated by the redox state of the enzymes. Methods Mol Biol 2010; 644: 67-90.
152. Aronoff DM, Boutaud O, Marnett LJ, Oates JA. Inhibition of prostaglandin H2 synthases by salicylate is dependent on the oxidative state of the enzymes. Adv Exp Med Biol 2003; 525: 125-128.
153. Nourooz-Zadeh J, Tajaddini-Sarmadi J, McCarthy S, Betteridge DJ, Wolff SP. Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes 1995; 44: 1054-1058.
154. Antonipillai I, Nadler J, Vu EJ, Bughi S, Natarajan R, Horton R. A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient and early renal disease. J Clin Endocrinol Metab 1996; 81: 1940-1945.
155. Karaouzene N, Merzouk H, Aribi M, Merzouk SA, Yahia Berrouiguet A, Tessier C etal. Effects of the association of aging and obesity on lipids, lipoproteins and oxidative stress biomarkers: a comparison of older with young men. Nutr Metab Cardiovasc Dis 2010. [Epub ahead of print].
156. Raffaelli F, Nanetti L, D'Angelo M, Montecchiani G, Alidori A, Montesi L etal. Interactions between lipoproteins and platelet membranes in obesity. Obesity (Silver Spring) 2009; 17: 1375-1380.
157. Bala M, Chin CN, Logan AT, Amin T, Marnett LJ, Boutaud O etal. Acetylation of prostaglandin H2 synthases by aspirin is inhibited by redox cycling of the peroxidase. Biochem Pharmacol 2008; 75: 1472-1481.